Elon Musk says Neuralink’s brain implant for blindness is finished on the engineering side and is now waiting for regulators. In a post on X on October 30, 2026, he described the device, called Blindsight, as the company’s second product after its paralysis implant, Telepathy1. The post drew wide attention. But it did not come with new data, a trial start date or a change in the implant’s regulatory status. This article separates what was said from what is known.
What Musk announced
Musk wrote that Blindsight would let people see even if they are completely blind or have never seen. In his words:
“Our second product is called Blindsight and it will, as the name suggests, enable even those who are completely blind or have never seen to see. It is ready from an engineering standpoint. Just waiting on regulatory approval.”
That quote was reported by International Business Times UK, which stressed that these are Musk’s expectations, not a demonstrated medical result1. Jordan News also reported Musk’s view that the technology is ready from an engineering standpoint but still depends on regulatory approvals2.
In the same set of posts, Musk talked about Telepathy, the implant Neuralink already tests in people with paralysis. He said its output speed would one day beat the fastest human speech or typing, but gave no timetable1. He also said he hopes that within a few years the company can route signals from the brain’s movement and sensing areas to the limbs, so people with paralysis could use their hands and walk again2. Jordan News noted that restoring normal movement this way remains a future goal that has not been clinically proven2.
How Blindsight is meant to work
Normal sight starts in the retina, the light-sensing layer at the back of the eye, which turns light into electrical signals that the brain then turns into images. Disease or injury to the eyes or the optic nerve (the cable linking eye and brain) can break that chain and cause blindness1.
Blindsight is designed to go around that broken chain. A video camera captures images and sends the information wirelessly to an implant, which stimulates the parts of the brain that handle vision1. The target is the visual cortex, the area at the back of the brain that processes what we see2. In theory, this skips damaged eyes or optic nerves entirely2.
There is one important limit in that design. A reference summary of the device says it is being developed for people with total vision loss caused by optic nerve damage but with an intact visual cortex3. In other words, the brain’s vision area itself has to be working for this approach to have something to stimulate. Back in 2024, Musk went further, saying Blindsight could let even people who have lost both eyes and their optic nerve regain vision4.
Where it stands with regulators
Neuralink announced on September 17, 2024, that Blindsight had received Breakthrough Device Designation from the US Food and Drug Administration (FDA)1. This status is meant to speed up the development and review of medical devices for serious or life-threatening conditions4. At the time, the FDA had not commented on Neuralink’s announcement4.
Breakthrough status is not approval. It does not clear the device for general use, and designated devices still have to meet the FDA’s safety and effectiveness standards before they can be sold1. Jordan News likewise reported that the designation does not mean final approval, and that preparations are still under way to begin human trials2.
Musk’s phrase “waiting on regulatory approval” therefore most plausibly refers to permission to start testing in people, not to permission to sell the device. Neuralink has not announced a confirmed date to start human trials of Blindsight in the United States1. Its website invites people to sign up to a patient registry for updates on future US trials of visual prostheses (devices that try to replace lost sight)1.
What it does not show yet
Several things remain unknown:
- Whether it works in people. Neuralink has not announced that Blindsight has restored sight in any human participant1.
- Whether it is safe. Success depends on future clinical trials proving safety and effectiveness in humans2.
- What people would actually see. The question for blind people is whether testing can show that Blindsight is safe and gives useful visual perception1. “Seeing” could mean many things, from sensing light to recognizing objects, and no data yet show which, if any, the implant can deliver.
- When testing begins. No start date has been given1.
International Business Times UK summed it up: until trial results and regulatory decisions are available, Musk’s announcement remains an ambition, not proof of a working treatment1. It also reported that medical authorities describe the hardware as an early, experimental prosthesis rather than a proven cure1.
The paralysis implant alongside it
Telepathy, Neuralink’s first implant, reads brain signals and turns them into digital commands2. According to Jordan News, people with severe paralysis have used it to move a cursor, click, play games, write computer code and make digital art by thought2. The company’s trials are also exploring control of robotic arms2.
When Blindsight got its FDA status in 2024, the Telepathy trial was expected to take several years, with three patients enrolled; the second patient was using the implant to play video games and design 3D objects4. That gives Neuralink a track record of implanting devices in people. But reading signals out of the brain, as Telepathy does, is a different job from writing signals into the brain to create images, which is what Blindsight would need to do1.
Who is behind it
Neuralink is Musk’s brain-chip company, founded in 2016 to build implants that help disabled people regain abilities such as movement and communication4. The new claims come from Musk himself, posting on X1. No independent researchers or published studies are cited in the coverage of this announcement.
The post also became a political talking point. Commentator Megyn Kelly defended Musk on X, writing that he is “the man the Left regularly tries to villainise and wants thrown in jail”1. International Business Times UK noted that she did not name anyone and that her statement is opinion, not evidence of any coordinated effort1. None of that reaction bears on whether the implant works.
How it fits the field and what to watch next
Blindsight is one of several attempts to restore some sight to blind people by going around damaged parts of the visual system. Other groups work at the eye itself; Biohack recently covered one such approach in a study of gene therapy and camera goggles. Neuralink’s bet is to skip the eye altogether and talk to the brain directly2.
The next real development would be concrete steps toward testing in people:
- an announced start date or first participant for a US trial, which Neuralink has not yet given1;
- any public statement from the FDA about the device, which had not commented when the breakthrough status was announced4;
- details of who would be eligible, given that the design depends on a working vision area of the brain3;
- eventually, results showing whether the implant is safe and what, if anything, participants can perceive2.
Until then, Blindsight remains a designed device with a regulatory head start and no reported human results.
